Abcam

Abcam is a life-science research tools brand founded in Cambridge, England, in 1998. It began with a focused mission: make it easier for scientists to find and purchase reliable antibodies through the internet. The idea emerged from research difficulties encountered in a Cambridge laboratory studying BRCA2, where the availability, quality and practical-use information for antibodies could be inconsistent or difficult to assess. Abcam’s original online catalogue model sought to address that problem by combining a broad selection of research antibodies with product specifications, application information and experimental validation data. The company subsequently developed from an antibody supplier into a broader provider of protein research tools. Its portfolio includes primary and secondary antibodies, recombinant proteins, peptides, immunoassays, ELISA products, immunohistochemistry reagents, protein-detection products, biochemicals, cellular assays and epigenetics kits. Examples of its branded or associated technologies include SimpleStep ELISA Kits and FirePlex multiplex assay products. These tools support work in areas such as cell biology, immunology, neuroscience, cancer biology, infectious disease, metabolism, epigenetics, drug discovery and translational research. Abcam serves a diverse customer base comprising academic laboratories, public research organizations, hospitals, pharmaceutical companies and biotechnology firms. Its international operating model combines digital product discovery and ordering with regional commercial, technical and research capabilities. The company has operated from multiple locations internationally and has emphasized online access to technical documentation, application data, protocols and product-selection resources. This information-centered approach has been an important part of its positioning in a market where reproducibility, target specificity and application performance are major purchasing considerations. Expansion has also occurred through acquisitions and internal portfolio development. Acquired businesses added capabilities in mitochondrial research, biochemical modulation, rabbit monoclonal antibodies, multiplex biomarker assays, recombinant antibody discovery, proteomics, immunology, fluorescence chemistry and related assay technologies. In 2019, Abcam moved its global headquarters to the Cambridge Biomedical Campus, connecting the company with a major UK cluster for biomedical science and healthcare research. Abcam was formerly a publicly traded company on Nasdaq and the London Stock Exchange. On 28 August 2023, Danaher announced an agreement to acquire the company for approximately $5.7 billion in cash at $24 per share. Following shareholder approval, regulatory clearances and approval by the High Court of Justice of England and Wales, the transaction was completed on 6 December 2023. Abcam became an indirect wholly owned subsidiary of Danaher, and its shares ceased trading on Nasdaq. The Abcam brand continues to operate in the life-science research tools market under Danaher ownership, while no longer functioning as an independent listed company.

Abcam was established in Cambridge, England, in 1998 by Jonathan Milner, Tony Kouzarides and David Cleevely. The founding concept arose from the practical difficulty of obtaining dependable antibodies for biomedical research. Milner was working as a postdoctoral researcher in Kouzarides’ laboratory on BRCA2-related research, and the team saw an opportunity to create a web-based service that would make research antibodies easier to locate and buy while providing clearer information about their applications and limitations. The company initially concentrated on antibodies and built its identity around a broad catalogue, online ordering and supporting technical information. Over time, it expanded into adjacent protein-research categories, including immunoassays, peptides, recombinant proteins and protein-detection products. It also added non-antibody technologies such as biochemicals, cellular assays and epigenetics kits. This diversification allowed Abcam to address a wider range of experimental workflows, from target detection and tissue staining to biomarker measurement, cell analysis and functional protein studies. Acquisitions were an important part of the expansion strategy. In 2011, Abcam acquired MitoSciences, which developed mitochondrial research products and monoclonal antibodies, and completed the purchase of Ascent Scientific, a UK supplier of biochemical products used to modulate protein function. In 2012, it acquired Epitomics, adding expertise in rabbit monoclonal antibodies and operations associated with the United States and China. In 2015, Abcam acquired Firefly BioWorks, whose multiplex assay technology was later associated with the FirePlex brand, and acquired AxioMx, a provider of custom recombinant antibody discovery and development services. Abcam acquired Calico Biolabs in 2019. In the same year, it moved its global headquarters to the Cambridge Biomedical Campus, reinforcing its connection with a major concentration of medical, scientific and healthcare organizations. In January 2020, the company acquired Expedeon’s Proteomics and Immunology business, including Innova and TGR Biosciences. In March 2020, it acquired Marker Gene Technologies, adding capabilities in biology, organic synthesis and fluorescence chemistry for detection-tool development. The company operated as a public business for a period and was listed on both Nasdaq and the London Stock Exchange. On 28 August 2023, Danaher announced a definitive agreement to acquire Abcam for approximately $5.7 billion in cash at $24 per share. The transaction received shareholder approval in November 2023 and proceeded after regulatory clearances and approval by the High Court of Justice of England and Wales. Completion took place on 6 December 2023. Abcam consequently became an indirect wholly owned subsidiary of Danaher, and its shares stopped trading on Nasdaq. The brand remains active as part of Danaher’s life-science portfolio, continuing to supply research antibodies, proteins, assays and related tools to customers internationally.

1. 2023Danaher completes acquisition

   Danaher completes its acquisition of Abcam on 6 December, making the company an indirect wholly owned subsidiary.

   Source
2. 2020Expansion of proteomics, immunology and detection capabilities

   Abcam acquires Expedeon’s Proteomics and Immunology business and later acquires Marker Gene Technologies.

   Source
3. 2019Headquarters move to Cambridge Biomedical Campus

   Abcam relocates its global headquarters to the Cambridge Biomedical Campus.

   Source
4. 2016Firefly becomes FirePlex

   Firefly BioWorks is rebranded as FirePlex, supporting Abcam’s multiplex assay portfolio.

   Source
5. 2015Firefly BioWorks and AxioMx acquisitions

   Abcam adds multiplex assay technology through Firefly BioWorks and recombinant antibody discovery services through AxioMx.

   Source
6. 2012Epitomics acquisition

   The acquisition adds rabbit monoclonal antibody development and production capabilities in the United States and China.

   Source
7. 2011MitoSciences and Ascent Scientific acquisitions

   Abcam expands into mitochondrial research products, monoclonal antibodies and biochemical tools through two acquisitions.

   Source
8. 1998Abcam is founded in Cambridge

   Jonathan Milner, Tony Kouzarides and David Cleevely establish Abcam around an internet-based model for supplying research antibodies with clearer product information.

   Source

A global research-reagents and life-science tools brand for biomedical and biological research, differentiated by breadth of catalogue, application validation, technical information and digital purchasing infrastructure.

• Research antibodiesResearch reagents

  Abcam’s foundational product category includes antibodies used to detect, quantify or localize proteins in biomedical experiments. Applications include western blotting, immunohistochemistry, immunofluorescence, flow cytometry and related protein-analysis workflows. The range supports research in cancer, neuroscience, immunology, cell biology and other disciplines.

• Recombinant proteins and peptidesProtein research reagents

  These products provide defined protein or peptide materials for assay development, functional studies, immunology, biochemical experiments and drug-discovery research. They extend Abcam’s offering beyond detection reagents into experimental systems that require proteins as standards, stimuli, targets or analytical inputs.

• SimpleStep ELISA Kits and immunoassaysImmunoassays

  Abcam’s immunoassay portfolio supports quantitative or comparative measurement of proteins, antigens and other biological targets. ELISA products are designed for laboratory workflows that require standardized plate-based detection, while related assay formats address different sample types and research questions.

• Immunohistochemistry productsProtein detection

  Immunohistochemistry reagents and staining products help researchers visualize target proteins in tissue sections. They are used in pathology-oriented research, cancer biology, developmental biology and studies of tissue organization and disease mechanisms.

• FirePlex multiplex assaysMultiplex assays2016

  FirePlex technologies support multiplex measurement of biological targets, including microRNA and other biomarkers. The platform originated with Firefly BioWorks and added a capability for analyzing multiple targets in a single assay, supporting biomarker research and sample-limited studies.

• Biochemicals, cellular assays and epigenetics kitsResearch tools

  This broader group includes reagents for biochemical experiments, cellular analysis and epigenetics research. It reflects Abcam’s development from an antibody-focused supplier into a more comprehensive provider of tools for investigating biological pathways, molecular regulation and cellular responses.

• 2023Danaher acquisition of AbcamM&A

  Danaher sought to expand its life-science tools activities through the addition of Abcam’s research-reagent portfolio and international customer base.

  What changed. Danaher agreed to acquire Abcam for approximately $5.7 billion in cash at $24 per share and completed the transaction on 6 December 2023.

  Aftermath. Abcam became an indirect wholly owned subsidiary of Danaher, its shares ceased trading on Nasdaq and the brand continued within Danaher’s life-science operations.

  Transaction value. Approximately $5.7 billion (Announced 28 August 2023; completed 6 December 2023)

  Source
• 2020Expansion through Expedeon and Marker Gene Technologies acquisitionsM&A

  Abcam aimed to extend its proteomics, immunology, assay, labeling and biological detection capabilities.

  What changed. Abcam acquired Expedeon’s Proteomics and Immunology business and later acquired Marker Gene Technologies.

  Aftermath. The transactions added the Innova and TGR Biosciences businesses and expertise in organic synthesis and fluorescence chemistry.

  Source
• 2015Acquisition of Firefly BioWorks and AxioMxM&A

  Abcam pursued adjacent technologies in multiplex biomarker analysis and custom recombinant antibody discovery.

  What changed. The company acquired Firefly BioWorks and AxioMx, adding multiplex assay and recombinant antibody development capabilities.

  Aftermath. Firefly’s technology became associated with the FirePlex portfolio, while AxioMx strengthened custom antibody services.

  Source
• 2011Acquisition of MitoSciencesM&A

  Abcam sought to broaden its antibody and immunoassay capabilities into mitochondrial research and related disease areas.

  What changed. Abcam announced the acquisition of MitoSciences, a US biotechnology company focused on mitochondrial research products and monoclonal antibodies.

  Aftermath. The transaction expanded Abcam’s portfolio for research into cancer, neurodegeneration and metabolic disorders.

  Source

• 2023Danaher announces agreement to acquire Abcam

  Danaher announced a definitive agreement to acquire Abcam for approximately $5.7 billion in an all-cash transaction valued at $24 per share.

  M&A
  Source
• 2023Danaher completes acquisition of Abcam

  After shareholder approval, regulatory clearances and court approval in England and Wales, Danaher completed the acquisition on 6 December 2023. Abcam became an indirect wholly owned subsidiary and its Nasdaq trading ended.

  M&A
  Source

1. Abcam
2. Danaher completes acquisition of Abcam
3. Abcam official website
4. Danaher宣布收购Abcam的协议